SCHEMBL6538484

SCHEMBL6538484

CCCCCCO[CH]CCCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.51
SIGMAR1 Q99720 2/20 0.44
OPRM1 P35372 2/20 0.42
DRD3 P35462 2/20 0.42
CHRM2 P08172 1/20 0.42
HTR1A P08908 1/20 0.42
ADRA2A P08913 1/20 0.42
CHRM1 P11229 1/20 0.42
DRD1 P21728 1/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42
ADRA1A P35348 1/20 0.42
SLC6A3 Q01959 1/20 0.42
PPARA Q07869 1/20 0.42
CETP P11597 1/20 0.42
HTR2A P28223 1/20 0.42
BCHE P06276 2/20 0.41
IDO1 P14902 1/20 0.41
DRD2 P14416 1/20 0.40
OPRD1 P41143 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6538944 0.95 KCNH2 (0.54) KCNH2SIGMAR1CHRM2ADRA2ACHRM1
SCHEMBL6538967 0.94 KCNH2 (0.51) KCNH2SIGMAR1OPRM1DRD3CHRM2
SCHEMBL6756009 0.92 KCNH2 (0.45) KCNH2SIGMAR1PPARACETPHTR2A
SCHEMBL6539292 0.90 SIGMAR1 (0.46) KCNH2SIGMAR1PPARACETPIDO1
SCHEMBL2761591 0.81 KCNH2 (0.45) KCNH2CETP
SCHEMBL2762162 0.81 KCNH2 (0.45) KCNH2CETP
SCHEMBL8567635 0.81 ADRA1A (0.48) KCNH2SIGMAR1OPRM1DRD3CHRM2
SCHEMBL2761482 0.80 LTA4H (0.44) KCNH2SIGMAR1
SCHEMBL10731438 0.78 CETP (0.47) KCNH2SLC6A4PPARACETP
SCHEMBL22268758 0.78 KCNH2 (0.59) KCNH2SIGMAR1CHRM2ADRA2ACHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6743776-B2 ANTIFUNGAL, BETA-1,3-GLUCAN SYNTHASE INHIBITOR, PNEUMOCYSTIS CARINII; AMIDATION FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-01 US disclosed
US-20020193560-A1 CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY ASTELLAS PHARMA INC. (JP) 2002-12-19 US disclosed
EP-0941236-A1 CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-09-15 EP disclosed
WO-1998023637-A1 CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193560-A1 CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY NGLY1, CHIT1, MANBA KCNH2 2461/4885SIGMAR1 1309/4885OPRM1 4541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.